Mammografische Eigenschaften als Biomarker für das Rezidivrisiko von DCIS

20–40 % aller duktalen In-situ-Karzinome (DCIS) der Brust rezidivieren. Die Identifizierung der Frauen, die von einer adjuvanten Bestrahlung profitieren, ist entscheidend für eine passgenaue, personalisierte Brustkrebstherapie. Nützlich ist die molekulargenetische Abklärung, die eine Einteilung in Risikogruppen ermöglicht. Die Studie zeigt, dass die Risikoabschätzung auch mit dem mammografischen Kalzifikationsmuster gelingt.

Publikationsverlauf

Artikel online veröffentlicht:
25. Juni 2020

• Literatur

• 1 Ernster VL, Ballard-Barbash R, Barlow WE. et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. Journal of the National Cancer Institute 2002; 94 (20) 1546-54
• 2 Donker M, Litiere S, Werutsky G. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2013; 31 (32) 4054-4059
• 3 Group EBCC, Group ER, Bijker N. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006; 24 (21) 3381-3387
• 4 Correa C, McGale P, Taylor C. Early Breast Cancer Trialists' Collaborative G. et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010; 2010 (41) 162-177
• 5 Holmberg L, Garmo H, Granstrand B. et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008; 26 (08) 1247-1252
• 6 Solin LJ, Gray R, Baehner FL. et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. Journal of the National Cancer Institute 2013; 105 (10) 701-710
• 7 Rakovitch E, Nofech-Mozes S, Hanna W. et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast cancer research and treatment 2015; 152 (02) 389-398
• 8 Pinker K, Chin J, Melsaether AN. et al. Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment. Radiology 2018; 287 (03) 732-747
• 9 Leithner D, Horvat JV, Ochoa-Albiztegui RE. et al. Imaging and the completion of the omics paradigm in breast cancer. Der Radiologe 2018; 58 (Suppl. 01) 7-13
• 10 Pinker K, Shitano F, Sala E. et al. Background, current role, and potential applications of radiogenomics. Journal of magnetic resonance imaging: JMRI 2018; 47 (03) 604-620
• 11 Evans A, Pinder S, Wilson R. et al. Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings. Am J Roentgenol American journal of roentgenology 1994; 162 (06) 1307-1311
• 12 Yamada T, Mori N, Watanabe M. et al. Radiologic-pathologic correlation of ductal carcinoma in situ. Radiographics 2010; 30 (05) 1183-1198